Skip to main content
. Author manuscript; available in PMC: 2013 Feb 1.
Published in final edited form as: Eur J Neurosci. 2012 Jan 25;35(3-4):562–571. doi: 10.1111/j.1460-9568.2011.07972.x

Figure 6. T cell proliferation studies showed no significant differences between p66-KO and WT mice in MOG immunoreactivity.

Figure 6

Using standard EAE protocol, p66-KO and WT mice were immunized with MOG 35-55 peptide. Ten days post-immunization, lymph nodes were collected for proliferation studies. Lymph node cultures treated with positive control IL-2 and MOG 35-55 peptide (25mg/mL) showed no significant differences in proliferative responses between the p66-KO and WT groups. SI = Stimulation index; NS = difference not significant (p>0.05).